Compare MRKR & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRKR | AIMD |
|---|---|---|
| Founded | N/A | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.6M | 16.9M |
| IPO Year | N/A | N/A |
| Metric | MRKR | AIMD |
|---|---|---|
| Price | $1.19 | $2.06 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $10.25 | N/A |
| AVG Volume (30 Days) | ★ 271.0K | 38.7K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,694,988.00 | $113,037.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.06 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 178.19 |
| 52 Week Low | $0.81 | $1.78 |
| 52 Week High | $5.95 | $5.00 |
| Indicator | MRKR | AIMD |
|---|---|---|
| Relative Strength Index (RSI) | 63.24 | 32.46 |
| Support Level | $1.15 | $2.02 |
| Resistance Level | $1.27 | $2.27 |
| Average True Range (ATR) | 0.10 | 0.18 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 87.50 | 20.15 |
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.